TL;DR
A CDC analysis of 18,301 adult RSV hospitalizations across eight seasons found that 8.6% of patients died in hospital or within 30 days after discharge. Of those deaths, 467 occurred after discharge to somewhere other than hospice; researchers said the findings point to risk in the month after hospitalization, but cannot establish that RSV caused the deaths.
A CDC analysis of 18,301 adults hospitalized with RSV from 2014 to 2024 found that 8.6% died in the hospital or within 30 days of discharge, including 467 people who died after being discharged somewhere other than hospice. The findings, presented by CDC physician Michael Melgar at the IDWeek annual meeting, highlight a period of elevated concern after discharge, although the analysis does not establish that RSV caused each death.
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers counted 1,565 deaths during hospitalization or in the 30 days after discharge. More than half, 812, occurred in the hospital; 753 occurred after discharge. Of those post-discharge deaths, 286 people had been discharged to hospice, while 467 were discharged to a setting other than hospice. That latter group represented 2.6% of all adults in the analysis who had been hospitalized with RSV.
The proportion of patients who died during hospitalization or within 30 days of discharge was broadly steady across the eight seasons, ranging from 7.4% in 2018-2019 to 9.7% in 2015-2016. The share who died after discharge somewhere other than hospice ranged from 1.8% in 2022-2023 to 3.2% in 2019-2020. These are observations from the study periods, not estimates of an individual patient’s risk.
Most people who died in hospital or within 30 days after discharge were 65 or older (81.3%), and 89% had at least one underlying medical condition. Nearly half had been admitted to an intensive care unit, and 29.1% received invasive mechanical ventilation. Patients who died after discharge were older on average than those who died in hospital, while ICU admission and ventilation were less common in the post-discharge group.
The Risk May Continue After Discharge
The findings draw attention to deaths occurring after a patient has left the hospital, a period that may receive less attention than the acute illness. Melgar said the patients discharged somewhere other than hospice were likely sent home or to another level of care, and may not have been expected to die within a month. The data do not show what care they received after discharge or whether earlier follow-up would have changed outcomes.
For clinicians and health systems, the results support examining discharge planning and early follow-up for adults hospitalized with RSV, as Melgar suggested. The analysis also reinforces public health messaging around vaccination for eligible adults. It does not measure the effectiveness of any particular follow-up approach, nor does it show that vaccination would have prevented the recorded deaths.
RSV can cause severe lower respiratory illness, especially in older adults and people with underlying conditions. The study also notes that adults hospitalized with RSV may face cardiorespiratory events after discharge, including heart attack or stroke. The mortality figures make the post-hospital period relevant to care planning, while leaving the causes of individual deaths unresolved.
Products Worth Considering

Levoit Core 300S-P Smart WiFi Air Purifier

Levoit Vital 200S-P Smart Air Purifier for Large Rooms (Up to 1875 sq ft)

Blueair 2-in-1 Pro DH5i Air Purifier and Humidifier
As an affiliate, we earn on qualifying purchases.
Eight Seasons of RSV Surveillance
The CDC team used data from the Respiratory Virus Hospitalization Surveillance Network (RESP-NET), which tracks laboratory-confirmed influenza, COVID-19 and RSV hospitalizations in 14 states. RSV cases in this analysis were identified using diagnostic codes for RSV pneumonia, acute bronchitis due to RSV or acute bronchiolitis due to RSV. The study covered eight RSV seasons between 2014 and 2024.
Adult RSV vaccines became available during the 2023-2024 season. The CDC recommends a one-time dose of any of three FDA-licensed RSV vaccines for adults 75 or older and for adults ages 50 to 74 at increased risk of severe RSV. The source report cites 75% vaccine effectiveness against RSV hospitalization. Melgar said investigators did not examine vaccination status among patients hospitalized during the season in which adult vaccination began, so this analysis cannot determine the vaccine’s effect on its mortality findings.
“We think this latter category is the most concerning, as these patients were likely discharged home or to some higher level of care — but they were probably not expected to die within a month of the hospitalization with RSV infection.”
— Michael Melgar, MD, CDC, speaking at the IDWeek annual meeting
Causes and Vaccine Effects Remain Unknown
The analysis records deaths after RSV hospitalization but does not establish that RSV caused each death. Some patients may have died from other illnesses or complications, and the study does not provide case-by-case causes of death. It also cannot determine whether stronger discharge planning or earlier follow-up would have prevented any deaths.
Researchers did not assess vaccination status among the hospitalized patients during the 2023-2024 season, when adult RSV vaccines were introduced. The results also have limits: RESP-NET relies on clinician-directed testing, so some hospitalizations may have gone undetected, and findings from its 14 participating states may not represent the entire United States. The report describes the findings as preliminary.
Follow-Up Research and Prevention
The findings were presented at IDWeek, and further research would be needed to clarify causes of post-discharge deaths, compare outcomes by vaccination status and evaluate whether follow-up interventions affect risk. The analysis itself does not report a scheduled next study or policy change.
For now, the CDC’s stated adult vaccination recommendations remain the relevant prevention guidance: a one-time dose for adults 75 or older and for adults 50 to 74 at increased risk of severe RSV. The study’s authors also pointed to discharge planning and early follow-up as areas for attention. How those approaches should be designed, and whether they reduce mortality, remains untested in these results.
Key Questions
What did the CDC analysis find?
Among 18,301 adults hospitalized with RSV across eight seasons from 2014 to 2024, 8.6% died during hospitalization or within 30 days after discharge.
How many people died after leaving the hospital?
There were 753 deaths within 30 days after discharge. Of those, 286 patients had been discharged to hospice and 467 to somewhere other than hospice.
Does the study show RSV caused these deaths?
No. The analysis counted deaths after RSV hospitalization but could not establish that RSV was the cause of each death. Some deaths may have resulted from other conditions.
Who is eligible for the CDC-recommended RSV vaccine?
The CDC recommends a one-time dose of an FDA-licensed RSV vaccine for adults 75 or older and adults ages 50 to 74 at increased risk of severe RSV. The study did not determine the effect of vaccination on the deaths it recorded.
Source: rss
